CASI Pharmaceuticals annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
CASI Pharmaceuticals Capital Expenditures (CapEx) Growth & History (CASIF)
CASI Pharmaceuticals's capital expenditures (capex) was $16,000 for fiscal 2025.
View full CASI Pharmaceuticals company overviewCASI Pharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $16,000 | −$207,000 | −92.83% |
| 2024 | 2024-12-31 | $223,000 | $19,000 | +9.31% |
| 2023 | 2023-12-31 | $204,000 | −$5.4M | −96.36% |
| 2022 | 2022-12-31 | $5.6M | −$3.3M | −37.26% |
| 2021 | 2021-12-31 | $8.9M | $7.4M | +496.73% |
| 2020 | 2020-12-31 | $1.5M | — | — |
CASI Pharmaceuticals capital expenditures (capex) trends
Over the last five fiscal years, CASI Pharmaceuticals's capital expenditures (capex) decreased from $1.5M to $16,000, a change of −$1.5M.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CASI Pharmaceuticals source filings ↗